[go: up one dir, main page]

WO1999041279A3 - Methods and compositions comprising the use of blocked b-amyloid peptide - Google Patents

Methods and compositions comprising the use of blocked b-amyloid peptide Download PDF

Info

Publication number
WO1999041279A3
WO1999041279A3 PCT/US1999/003231 US9903231W WO9941279A3 WO 1999041279 A3 WO1999041279 A3 WO 1999041279A3 US 9903231 W US9903231 W US 9903231W WO 9941279 A3 WO9941279 A3 WO 9941279A3
Authority
WO
WIPO (PCT)
Prior art keywords
blocked
compositions
methods
amyloid peptide
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/003231
Other languages
French (fr)
Other versions
WO1999041279A2 (en
Inventor
David G Lynn
Stephen C Meredith
Timothy S Burkoth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Priority to AU26004/99A priority Critical patent/AU2600499A/en
Publication of WO1999041279A2 publication Critical patent/WO1999041279A2/en
Publication of WO1999041279A3 publication Critical patent/WO1999041279A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates generally to amyloidogenesis. More particularly, it concerns the use of amyloidogenic proteins that have been blocked at the N- and/or C-termini and/or side chains to prevent their aggregation into amyloidogenic plaques. Particular aspects of the present invention describe the methods and compositions of inhibition of plaque formation in amyloidoses, for example, Alzheimer's Disease.
PCT/US1999/003231 1998-02-13 1999-02-12 Methods and compositions comprising the use of blocked b-amyloid peptide Ceased WO1999041279A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU26004/99A AU2600499A (en) 1998-02-13 1999-02-12 Methods and compositions comprising the use of blocked b-amyloid peptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7465898P 1998-02-13 1998-02-13
US60/074,658 1998-02-13

Publications (2)

Publication Number Publication Date
WO1999041279A2 WO1999041279A2 (en) 1999-08-19
WO1999041279A3 true WO1999041279A3 (en) 1999-10-28

Family

ID=22120866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003231 Ceased WO1999041279A2 (en) 1998-02-13 1999-02-12 Methods and compositions comprising the use of blocked b-amyloid peptide

Country Status (2)

Country Link
AU (1) AU2600499A (en)
WO (1) WO1999041279A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395833B1 (en) 2001-05-31 2013-02-27 Adlyfe, Inc. Misfolded protein sensor method
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
DK2465533T3 (en) 2004-02-20 2015-04-20 Ac Immune Sa Methods and compositions comprising supramolecular constructs
WO2006088823A2 (en) 2005-02-15 2006-08-24 Adlyfe, Inc. Method for detecting misfolded proteins and prions
JP5097206B2 (en) * 2006-07-28 2012-12-12 エイディーライフ インコーポレイティッド Peptide probes for diagnosis and treatment
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
WO2012055933A1 (en) 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
WO2013065343A1 (en) 2011-10-31 2013-05-10 株式会社 島津製作所 Peptide-hinge-free flexible antibody-like molecule
WO2021100744A1 (en) * 2019-11-19 2021-05-27 Ｔａｏヘルスライフファーマ株式会社 CROSSLINKED PRODUCT OF AMYLOID-β PROTEIN (Aβ) ABLE TO BE SUBSTITUTE FOR AMYLOSPHEROID (ASPD), AND ANALYSIS OF ASPD

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028471A1 (en) * 1995-03-14 1996-09-19 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5721106A (en) * 1991-08-13 1998-02-24 Regents Of The University Of Minnesota In Vitro method for screening β-amyloid deposition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721106A (en) * 1991-08-13 1998-02-24 Regents Of The University Of Minnesota In Vitro method for screening β-amyloid deposition
WO1996028471A1 (en) * 1995-03-14 1996-09-19 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURKOTH, TIMOTHY S. ET AL: "C-Terminal PEG blocks the irreversible step in.beta.- amyloid (10-35) fibrillogenesis", J. AM. CHEM. SOC., vol. 120, no. 30, 5 August 1998 (1998-08-05), pages 7655 - 7656, XP002112798 *
ESLER WP ET AL: "Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence", BIOCHEMISTRY, XP002113078 *
INADA Y ET AL: "Biomedical and biotechnological applications of PEG-and PM-modified proteins", TIBTECH, vol. 13, March 1995 (1995-03-01), pages 86 - 91, XP002113079 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use

Also Published As

Publication number Publication date
AU2600499A (en) 1999-08-30
WO1999041279A2 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
WO1999041279A3 (en) Methods and compositions comprising the use of blocked b-amyloid peptide
WO1999045907A3 (en) Metal chelators for use in the treatment of alzheimer's disease
WO1997026919A3 (en) Method of imaging amyloid deposits
CA2123739A1 (en) Formulations containing carotenoids and procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
MX9504067A (en) Cosmetic compositions containing a ceramide type lipid compound and a peptide with a fatty chain and uses therefrom.
CA2304969A1 (en) Mouth hygienic composition for the treatment of halitosis
EP1166767A3 (en) Skin care product containing hydroxyproline or N-acylated hydroxyproline derivatives
AU2002219824A1 (en) Compositions and methods for diagnosing alzheimer's disease
BR9910490A (en) Materials and methods for creating insects, mites and other beneficial organisms
PT1095061E (en) Peptides based on the sequence of human lactoferrin and their use
CA2252661A1 (en) Storage stable dentifrice composition containing casein glycomacropeptide
AU4073901A (en) Novel pharmaceutical or dietetic mushroom-based compositions
CA2071146A1 (en) Taste preserving, mild oral hygiene compositions
CA2309351A1 (en) Oral cleansing: methods and compositions
UY25591A1 (en) IMPROVED ORAL COMPOSITIONS FOR THE CONTROL AND PREVENTION OF DENTAL CALA, BAD ODOR, PLAQUE AND GINGIVITIS PLACA AND GINGIVITIS
WO2002062304A3 (en) Cosmetic and/or pharmaceutical agents containing an acylated amino acid and a protein condensate
WO2002060394A3 (en) Revitalising active complex for the skin
ATE174786T1 (en) ORAL PREPARATIONS FOR THE TREATMENT OF PLAQUE AND GINGIVITIS CONTAINING A NON-CATIONIC ANTIBACTERIAL ACT AND A BICARBONATE SALT
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
DE60221989D1 (en) ORAL PRODUCTS CONTAIN A FLUOR-ION VECTOR AND ANTIOXIDANT
YU45103A (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
AU5006499A (en) Compositions and methods for the treatment or prevention of pulmonary infections
WO2001043705A3 (en) Compositions containing a retinoid and a stilbene for skin care
ATE418870T1 (en) COFFEE COMPOSITION
CA2241825A1 (en) New monofunctionalized edta, dtpa and ttha derivatives and their use in medical diagnosis and therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase